Ordaōs completes acquisition of the Carterra®LSA® Platform to optimize its machine-driven drug design system
Acquiring Company
Ordaos
Acquired Company
Carterra, Inc.
New YorkSalt Lake CityBiotechnologyHealth CareArtificial IntelligenceBiotechnologyPharmaceuticalDescription
Ordaōs, a machine-driven drug design company, has successfully acquired the LSA® platform from Carterra, a provider of high-throughput technologies for the discovery of novel therapeutic candidates. This acquisition will enable Ordaōs to further enhance its technological capabilities and expedite the design of innovative new drug candidates across therapeutic areas, especially for challenging diseases.
Quick answer
Ordaos is acquiring Carterra, Inc., announced March 11, 2024. Ordaos is based in New York, New York, United States.
- Who acquired Carterra, Inc?
- Ordaos agreed to acquire Carterra, Inc. on March 11, 2024.
- How much did Ordaos pay for Carterra, Inc?
- The deal value was not disclosed.
- What does Ordaos do?
- Ordaōs is a human-enabled, machine-driven drug design company.
- Where are Ordaos and Carterra, Inc. based?
- Ordaos is based in New York, New York, United States. Carterra, Inc. is based in Salt Lake City, Utah, United States.
- Who are the decision-makers at Ordaos?
- Fundz holds 1 contact at Ordaos. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- Eli Lilly and Company acquires manufacturing facility from Nexus Pharmaceuticals to expand U.S. capacity (April 22, 2024)
- Future Pak proposes acquisition of Vanda Pharmaceuticals for $7.25 to $7.75 per share in cash (April 17, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Juvisé Pharmaceuticals acquires rights to MS therapy Ponvory outside North America (April 2, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
Who to call at Ordaos, and when
When Ordaos changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ordaos raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ordaos, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ordaos. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ordaos makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Carterra, Inc.?
Carterra, Inc. was acquired by Ordaos, based in New York. The deal was reported on March 11, 2024. Ordaōs is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods. Ordaos is privately held and operates in Biotechnology.
When did Ordaos acquire Carterra, Inc.?
Ordaos's acquisition of Carterra, Inc. was reported on March 11, 2024. Ordaōs, a machine-driven drug design company, has successfully acquired the LSA® platform from Carterra, a provider of high-throughput technologies for the discovery of novel therapeutic candidates. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Carterra, Inc. do?
Carterra® is privately held and is the leading provider of high-throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. It is privately held, operating in Biotechnology, and is based in Salt Lake City.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.